KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Return on Invested Capital (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Return on Invested Capital for 8 consecutive years, with 0.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 70.0% year-over-year to 0.64%, compared with a TTM value of 0.64% through Dec 2025, up 70.0%, and an annual FY2025 reading of 0.29%, up 35.0% over the prior year.
  • Return on Invested Capital was 0.64% for Q4 2025 at Teva Pharmaceutical Industries, up from 0.16% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.64% in Q4 2025 and bottomed at 0.24% in Q1 2021.
  • Average Return on Invested Capital over 5 years is 0.03%, with a median of 0.01% recorded in 2022.
  • The sharpest move saw Return on Invested Capital decreased -24bps in 2022, then soared 70bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.09% in 2021, then crashed by -275bps to 0.15% in 2022, then soared by 130bps to 0.05% in 2023, then crashed by -226bps to 0.06% in 2024, then soared by 1211bps to 0.64% in 2025.
  • Business Quant data shows Return on Invested Capital for TEVA at 0.64% in Q4 2025, 0.16% in Q1 2025, and 0.06% in Q4 2024.